Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica, an R&D biopharmaceutical company, has announced that ceftobiprole, the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from the Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections.
Subscribe to our email newsletter
The Swiss marketing authorization certificate may be used to facilitate regulatory approval and market entry in other countries including Asia and South America.
The regulatory dossier to Swissmedic was submitted by Basilea’s license partner Janssen-Cilag, a Johnson & Johnson company, who will commercialize ceftobiprole in Switzerland under the trade name Zevtera.
Ceftobiprole is marketed in Canada and is currently under regulatory review by regulatory authorities in the US, the EU and in other countries. Subject to approval, Basilea will co-promote ceftobiprole in the US and in the major European markets together with the respective Janssen-Cilag companies.
Anthony Man, CEO of Basilea, said: “We are delighted by this approval of ceftobiprole by Swissmedic. This is an important moment for our company and brings a novel and effective treatment against resistant bacteria to patients and physicians here in Switzerland.”